Skip to main content
Clinical Liver Disease logoLink to Clinical Liver Disease
. 2023 Jan 23;21(1):36–40. doi: 10.1097/CLD.0000000000000008

Progress toward hepatitis C elimination in Punjab, India

Karan Singla 1, Caroline E Boeke 2, Roli Tandon 1, Umesh Chawla 1, Magdalena Witschi 2, Karishma Mutreja 1, Shalu Gaugna 3, Gagandeep Grover 3
PMCID: PMC9875791  PMID: 36937775

INTRODUCTION: ESTABLISHMENT OF A PUBLIC SECTOR HEPATITIS C VIRUS CONTROL PROGRAM IN PUNJAB

The state of Punjab in India has a higher hepatitis C virus (HCV) prevalence compared to other states in the country; estimates range from 0.56% to 3.6%1,2 compared to 0.32% nationally.2 With a population of 28 million state-wide,3 this translates to 150,000 to 1 million anti-HCV positive people, many of whom have progressive chronic liver disease due to the virus. Infections are thought to be primarily fuelled by injecting drug use and unsafe medical injections, compounded by a low level of awareness among the general population about the disease and modes of transmission. However, limited information is available on the specific factors driving transmission locally.1

In 2016, due to the higher HCV prevalence and availability of direct acting antivirals, the Government of Punjab launched the Mukh Mantri Punjab Hepatitis C Relief Fund (MMPHCRF),4 becoming one of the first states in India to provide free antiviral treatment and subsidized diagnostic services for HCV at public sector facilities. Government buy-in and leadership were crucial factors in program success.

Punjab entered a public private partnership with an empaneled lab to ensure availability of diagnostic and confirmatory viral load tests to patients at an affordable rate at their treating facility. Other initial areas of focus included developing HCV testing and treatment guidelines and referral mechanisms, streamlining commodity procurement, ensuring consistent availability of diagnostics and treatment through supply chain management, building staff capacity through trainings at a large number of health facilities, and implementing an electronic monitoring and evaluation system to assess program progress and gaps.

NATIONAL VIRAL HEPATITIS CONTROL PROGRAM

In 2018, the National Viral Hepatitis Control Program (NVHCP) was launched to achieve elimination of HCV in India by 2030.5 With the launch of the national program along with HCV treatment, diagnostic services were made available free of cost to patients.6 The national program released treatment7 and diagnostic guidelines8 standardizing hepatitis management across the country. The guidelines were designed to be simple, evidence-based, and minimize visits to the health facility.

Individuals presenting to a clinician with clinical symptoms of and/or risk factors for HCV undergo a rapid diagnostic test for anti-HCV antibodies. If confirmed anti-HCV antibody positive, individuals are tested for current HCV viremia (HCV RNA viral load). Viremic patients undergo baseline investigations to detect presence of liver cirrhosis, if any. Twelve weeks after completing the treatment, patients are required to come back for a sustained virological response test (SVR12) to confirm whether the patient was cured. Diagnostic services including HCV antibody and RNA are available at all treatment centers. HCV RNA tests are processed under a public private partnership model; samples are collected at each facility and transported to a private facility in the state for testing on centralized equipment.

Figure 1 shows the algorithm for cost-effective management of hepatitis C in Punjab.

FIGURE 1.

FIGURE 1

Algorithm by National Viral Hepatitis Control Program (NVHCP) for cost-effective management of hepatitis C, as presented in National Operational Guidelines.6 Abbreviations: APRI, AST to platelet ratio index; DCV, daclatasvir; SOF, sofosbuvir; VEL, velpatasvir.

The increased focus and dedicated resources from the national program aided expansion in states including Punjab, while robust program monitoring and evaluation and research have helped identify new and strategic interventions. This manuscript describes strategies and approaches utilized in Punjab, India’s HCV program, with the ultimate goal of achieving HCV elimination in the state.

METHODS

This manuscript presents some aggregate-level program data in addition to describing strategies and approaches utilized by the program. Data were downloaded from Punjab’s HCV Management Information System (MIS) and include information from program initiation in 2016 through December 31, 2021. Data on number of treatment sites and number of patients screened were disaggregated by year and site type, and the total number of HCV services accessed across the cascade of care were included.

MOVING TOWARD ELIMINATION: STRATEGIES FOR SUCCESS

Rapid scale-up of screening and treatment sites

One key strategy for success in this state-wide program has been the rapid scale-up and decentralization of sites offering HCV services over time (Fig. 2). Initially, the program offered diagnostic and treatment services at all 22 district hospitals and 3 government medical colleges. Once the program was successfully established, the state envisaged pursuing a more active screening strategy to identify and treat people living with HCV. Hence, in October 2018, the state launched the strategy focused on high-risk populations by offering HCV screening to people living with HIV at 13 antiretroviral treatment centers and persons who inject drugs at 11 oral substitution therapy sites across the state. During the COVID-19 pandemic, to mitigate reduced mobility and increase treatment accessibility, these 24 antiretroviral treatment and oral substitution therapy sites additionally began to offer HCV treatment. Antiretroviral treatment and oral substitution therapy sites have contributed to ~10% of the total positive cases identified in the state (Fig. 3). Most recently, the program was decentralized to subdistrict hospitals. As of December 2021, there are a total of 68 sites successfully screening and treating people living with HCV, allowing for a large number of patients to access services.

FIGURE 2.

FIGURE 2

Treatment site expansion in Punjab.

FIGURE 3.

FIGURE 3

Number of anti-HCV positive tests from June 2016 to December 2021 at various service delivery sites in Punjab.

Building strong monitoring and evaluation systems

To monitor the program effectively, the Government of Punjab developed the MIS. Initially, the MIS was a comprehensive paper-based tool to capture patient-level data, which presented the challenge of large-scale data management and analysis. To overcome this, a mobile-based application was created along with tools in Microsoft Excel. The existing health care workers were trained on these tools to increase their uptake and usage. A web-based reporting dashboard was also developed for easy access to patient information at the individual as well at the aggregate level across the state program. The online reporting dashboard enabled real-time monitoring of program progress across the state and at substate levels. This enabled program managers to recommend corrective action as needed. Figure 4 depicts examples of the monitoring and evaluation tools developed.

FIGURE 4.

FIGURE 4

Examples of monitoring and evaluation tools developed.

The learnings from Punjab’s MIS system were instrumental in development of the National Viral Hepatitis Control Program Management Information System (NVHCP-MIS), developed and rolled out in the other states of the country.

Conducting rigorous research studies to guide program improvement

Analysis of the data collected in the MIS system identified program gaps requiring intervention and emphasized a need for additional evidence to support program improvement. Recent studies undertaken by states include an investigation of the primary local risk factors for HCV transmission, which will be used to develop prevention and screening strategies; a study to understand the primary reasons for early treatment cessation, to develop strategies to avert this loss to follow-up which occurs in nearly 15% of patients; and an analysis of HCV elimination costs and cost-savings,9 to understand resource requirements. The results from these studies will be used to guide program financing and strengthen the success of the program.

PROGRAM ACHIEVEMENTS TO DATE

Under the Punjab model of HCV management, 104,817 people living with HCV have been initiated on treatment in 5 years (Fig. 5). Out of these, 85,135 people living with HCV have completed treatment and 65,078 have had a SVR12 test; a total of 60,213 persons have a documented cure of their HCV infection. A high percentage of treatment initiations and a cure rate of ~93% are a testament to the programmatic and clinical success of the interventions introduced in the state. In addition, in 2017, Punjab launched the “injection safety implementation project”10 across all public health facilities to work toward reducing transmission with measures such as increasing availability of harm reduction services, disposal of contaminated needles and syringes, and promotion of disposable medical equipment and safe medical practices.

FIGURE 5.

FIGURE 5

Number of patients accessing HCV services in Punjab from June 2016 to December 2021. *Additionally, a total of 419 deaths has been recorded.

During COVID-19, in addition to antiretroviral treatment and oral substitution therapy sites beginning to offer HCV services to increase accessibility, multimonth dispensation and doorstep delivery of medicine were adopted during lockdown periods. Multimonth dispensation has now been adopted as a program strategy and is provided to patients at their request and at the clinician’s discretion.

THE WAY FORWARD

While many factors have contributed to the success of Punjab’s HCV program to date, a strong commitment and willingness from the government has been essential to program progress. Even with a well-established and mature program, more effort will be required to ensure universal access to screening, diagnosis, and treatment and achieve HCV elimination goals by 2030.

Some clear focus areas have been identified to accelerate progress toward elimination, such as improving accessibility by decentralizing services to the lowest levels of care (Community Health Centres and Primary Health Centres) and piloting telemedicine as a service delivery model. Whole blood diagnostic kits will be procured to facilitate screening and diagnostic tests during the same visit, thereby reducing the number of patient visits required for care. Active screening of high-risk groups and mass screening camps in vulnerable areas will be instrumental to improving case discovery and getting care to infected people. Evidence-driven program planning and increasing awareness among the general population and health care providers continue to be pivotal to ensuring program success. With additional focus on increased investment from the government and continuously evolving program strategies, Punjab is committed to achieving hepatitis elimination by 2030.

Acknowledgments

CONFLICT OF INTEREST

Nothing to report.

Footnotes

Abbreviations: DCV, daclatasvir; HCV, hepatitis C virus; MIS, management information system; MMPHCRF, Mukh Mantri Punjab Hepatitis C Relief Fund; NVHCP, National Viral Hepatitis Control Programme; SOF, sofosbuvir; SVR12, sustained virologic response at 12 weeks; VEL, velpatasvir.

Contributor Information

Karan Singla, Email: karan.singla091@gmail.com.

Caroline E. Boeke, Email: caroline.boeke@mail.harvard.edu.

Roli Tandon, Email: rtandon@clintonhealthaccess.org.

Umesh Chawla, Email: uchawla@clintonhealthaccess.org.

Magdalena Witschi, Email: magdalena.witschi@gmail.com.

Karishma Mutreja, Email: karishmamutreja@gmail.com.

Shalu Gaugna, Email: shalugaugna4489@gmail.com.

Gagandeep Grover, Email: dr.gagangrover@gmail.com.

REFERENCES


Articles from Clinical Liver Disease are provided here courtesy of American Association for the Study of Liver Diseases

RESOURCES